Consulting Archives

Top 20 Pharma Exceeds Recruitment Targets and Reduces Screen Failures Across 188 Sites

A top-20 pharmaceutical company was conducting a Phase III breast cancer study in 16 countries across North America, Europe, and

Doctor wearing gloves writes on paper beside a keyboard in an office setting.

Top 20 pharma accelerates training and enrollment across 650 Site Staff

A top-20 pharmaceutical company was planning a large Phase III trial of a new vaccine for a mosquitoborne viral disease.

Businessman cooperating with doctors in the hospital.

Insights on the FDA’s ELSA AI And What Changes Next

Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.

Concept of FDA Food and Drug Administration.

Preparing for Elsa: What Sponsors, Sites, and CROs Need to Know About the FDA’s New AI Era

Clinical Trial Budget Negotiations: A View From Each Side

Budget negotiation success hinges on clear communication and early resource sharing, helping sites and sponsors align expectations and avoid costly delays.

A digital interface showing a person interacting with transparent virtual icons related to compliance, such as "Policies," "Regulations," "Audit," "Guideline," "Requirement," and "Law." The word "COMPLIANCE" is prominently displayed in the center, surrounded by hexagonal icons representing various regulatory and legal concepts.

The Impact of ICH E6(R3) on U.S. and Canadian IRBs

Now that FDA has published the ICH E6(R3) Good Clinical Practice (GCP) guidance, aligning early with these requirements can prepare organizations for the future. ICH E6(R3) encourages ethics review committees to more intelligently apply their resources by enhancing efficiency without compromising participant safety or data integrity particularly regarding continuing review, informed consent, decentralized logistics, and data governance. Sponsors partnering with Advarra can be confident that their studies remain regulation-ready on both sides of the border today and E6(R3)-ready for tomorrow.

regulation, regulatory framework, compliance with regulations, regulatory standards, regulatory authorities, government regulation, industry regulation, financial regulation, regulatory policy, regulatory reforms, regulatory oversight, regulatory requirements, regulatory guidelines, regulatory reporting, regulatory enforcement, regulatory changes, regulatory implications, tile, word, letter tiles, background

Are you prepared for ICH E6 (R3)?

The third revision (R3) of the ICH E6 Guideline for Good Clinical Practice represents a significant modernization of global clinical research standards. Research organizations must critically evaluate both their clinical priorities and operational procedures to ensure compliance.

consulting featured image, including photos of clinical research professionals collaborating in an office

Consulting GxP services

GxP Solutions From early discovery to managing a global development portfolio, our industry-leading quality experts support your GxP compliance needs.

ICH E6(R3) Implementation Starts Now: Are You Ready?

The release of ICH E6(R3) in January 2025 marks the most significant evolution in Good Clinical Practice (GCP) guidelines in over a decade. More than a revision, E6(R3) marks a shift from traditional practices—making participant safety and data reliability not just priorities, but design drivers, and introducing risk-based proportionality as a foundational approach.